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Abstract 
Problem: Selecting appropriate medications for the aging population is challenging 
considering the number of chronic illnesses, prescriptions, and healthcare providers 
involved in their care, not to mention age related changes that impact pharmacokinetics.  
Significance: Inappropriate medications in geriatric patients can lead to adverse drug 
reactions (ADR).  Medication review tools can assist in the identification of potentially 
inappropriate medications (PIM) to avoid or closely monitor and prevent ADRs. 
Purpose: Describe and compare the application of select sections of the STOPP 
(Screening Tool of Older Persons Prescriptions) /START (Screening Tool to Alert to 
Right Treatment) and Beers Criteria in a geriatric population. Specific aims include 
describing and comparing: 1) the rate of PIM identified by sections of the Beers and 
STOPP Criteria, 2) the rate of  potential prescription omissions (PPO) identified by a 
section of the START Criteria, 3) the most common PIM or PPO drug classes identified, 
4) those with polypharmacy (>5 medications), and 5) the time for criteria application. 
Design: Retrospective descriptive, comparative chart review. 
Results:  A total of 468 medications were prescribed, an average of 7.43 per patient, with 
73.02% of patients with polypharmacy.   Beers Criteria identified 32 PIM in 39.7% while 
STOPP Criteria identified 67 PIM in 58.7%.  There was a high statistical difference 
between the number of PIM identified by the STOPP Criteria compared to the Beers 
Criteria (P=0.01).  A total of 16 PPO were identified with START Criteria in 17.5%.  
 Keywords: potentially inappropriate medication, potential prescription omissions, 
STOPP/START Criteria, Beers Criteria, adverse drug reactions 
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Chapter One: Introduction 
Introduction 
 In the United States (U.S.) the geriatric population, individuals 65 years and older, 
is growing (Patterson, Hughes, Kerse, Cardwell, Bradley, 2012; Hajjar, Cafiero, Hanlon, 
2007).  According to the 2010 census, 40 million Americans are 65 years of age and 
older. It is estimated the geriatric population will increase to 72 million or 20 percent of 
the national population by 2030 as the baby boomer generation reaches advanced age 
(Federal Interagency Forum on Aging, 2010).  Advanced age is associated with multiple 
normal aging changes.  These changes coupled with increased numbers of chronic 
diseases, increased numbers of healthcare providers, and multiple medications increase 
the complexity of the plan of care (Opondo, Eslami ,Visscher, Rooij, Verheij, Korevaar, 
Abu-Hanna, 2012; Cahir, Fahey, Teeling, Teljeur, Feely, Bennett, 2010; Ramaswamy, 
Maio, Diamon, Talati, Hartmann, Arenson, Roehl, 2010).   
 Forty percent of geriatric patients are currently taking five or more medications to 
treat their chronic diseases, placing them at a higher risk for potentially inappropriate 
medications (PIM), leading to possible adverse drug reactions (ADR) (Therapeutic 
Research Center, 2011; Pham & Dickman, 2007).  The most common ADRs include 
falls, fractures, and delirium which can impact functional ability and quality of life (Pham 
& Dickman, 2007).  For these reasons, the problem of PIM is a growing concern among 
providers who prescribe medications for the geriatric population.   
 Utilizing a medication screening tool in outpatient settings within the U.S. may be 
an effective method for preventing PIM and decreasing potential for ADR in geriatric 
patients. Medication screening tools are not meant to replace clinical judgement, but 
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rather to encourage closer monitoring or use of certain medications that could be 
potentially inappropriate or lead to ADR (Cahir et al, 2010).   The American Geriatric 
Society recommends the use of the Beers Criteria while the European Union Geriatric 
Medicine Society recommends the STOPP (Screening Tool of Older Persons’ 
Prescriptions)/START (Screening Tool to Alert doctors to Right Treatment) Criteria as a 
medication screening tool (Fick & Semla, 2012; Marcum & Hanlon, 2012).  Both criteria 
are explicit screening tools created by expert consensus panels that may be generalizable 
to the geriatric population (Cahir et al, 2010). 
 The Beers Criteria is organized into lists of medications to avoid or use with 
caution while the STOPP/START Criteria is organized by body system into lists of 
medication recommendations to either discontinue or initiate (American Geriatric 
Society, 2012; Gallagher, Ryan, Byrne, Kennedy, O’Mahony, 2007).  Considering the 
most common ADRs of falls and fractures, and the high number of geriatric patients 
suffering from musculoskeletal conditions, including osteoarthritis (OA) and osteoporosis 
(OP,) the Beers and STOPP Criteria have sections that may be useful to identify PIM and 
the START to identify potential prescription omissions (PPOs) associated with these 
common conditions.  Both criteria were reviewed in their entirety to ensure similar 
sections had been chosen from each criteria.  These sections include the 1) Beers history 
of falls and fracture section, 2) Beers pain medication section, 3) Beers history of gastric 
ulcers, 4) Beers history of chronic kidney disease, 5) STOPP central nervous system and 
psychotropic drugs section, 6) STOPP musculoskeletal drugs section, 7) STOPP drugs 
that adversely affect those prone to falls section, 8) STOPP analgesic drugs, and 9) 
START musculoskeletal drug sections. The Beers Criteria sections three and four were 
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selected due to their similarity with the STOPP/START Criteria's musculoskeletal 
sections (sections six and nine).  The STOPP Criteria section five was selected because of 
its similarity with the Beers history of falls and fractures section (section one).  Pain 
medication sections from each criteria were included because of the high risk for falls, 
confusion, and delirium in geriatric patients related to these medications.   
 Therefore, the purpose of this retrospective study was to describe and compare the 
application of select sections of the STOPP/START and Beers Criteria in a geriatric 
population in a musculoskeletal specialty setting in the United States. The aims of the 
present study were to describe and compare: 1) the rate of PIM identified by specific 
sections of the Beers Criteria (Appendix B) and specific sections of the STOPP Criteria 
(Appendix A), 2) the rate of  PPO identified by a specific section of the START Criteria 
(Appendix A), 3) the most common PIM or PPO drug classes identified by each criteria; 
4) identify those with polypharmacy (greater than 5 medications, and 5) the length of 
time for application of each criteria. 
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Chapter Two: Literature Review & Theoretical Framework 
Literature Review 
 Americans, age 65 years and older, increased by 15.3 percent between the years 
2000 and 2010.  Now one in every eight people is over 65 years of age (Administration 
on Aging U.S. Department of Health and Human Services, 2011).  Individuals over 65 
years of age experience multiple normal aging changes and an increased chronic disease 
burden.  Over two thirds of Medicare beneficiaries have two or more chronic diseases 
and 14 percent have six or more (Centers for Medicare & Medicaid Services, 2012). In 
2007, geriatric patients went to a healthcare provider seven times more often than 
younger patients and were three times more likely to be admitted to the hospital 
(Administration on Aging U.S. Department of Health and Human Services, 2011). 
Fall induced osteoporotic fractures are the leading cause of hospitalization in geriatric 
patients and falls are their leading cause of injury related death (CDC, 2012; Dalleur, 
Sinewine, Henrared, Losseau, Speybroeck, Boland, 2012).  One in three geriatric 
patients, 65 years and older, fall each year (Kojima, Akishit, Nakamaura, Nomaura, 
Ogawa, Iijima, Eto, Ouchi, 2010; Ziere, Dieleman, Hofman, Pols, Van der Cammen, 
Stricker, 2005; Hegeman, van den Bemt, Duysens, Limbeek, 2009).  The cost for 
treatment of falls in the U.S. was $30 billion in 2010 (CDC, 2012). 
 Several normal aging changes and chronic diseases may increase the risk of falls 
and consequently a serious injury, including fractures (Gallagher et al, 2007).  Some of 
these normal aging changes include hearing impairment, changes in vision, diminished 
coordination and reflexes, and decreased bone density (American Psychology 
Association, 1998; Whitaker, 2011; Klotz, 2009; Clyne, Bradley, Smith, Hughes, 
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Motterlini, Clear, McDonnell, Williams, and Fahey, 2013).   The most common chronic 
diseases that affect the musculoskeletal system are arthritis and osteoporosis (OP) 
(Kiebazk, 2002; Trivedi, Doll, Knaw, 2003).  Arthritis affects half of all geriatric 
patients, 75 years and older, and they often experience significantly decreased functional 
ability and quality of life as a result of their disease (CDC, 2010). Osteoporosis affects 52 
million men and women in the U.S. and  decreased bone density predisposes these men 
and women to fractures (Whitaker, 2011). One in three women and one in five men, age 
50 and older, will at some point suffer a fracture as a result of OP (International 
Osteoporosis Foundation, 2013). 
 A normal aging change in pharmacokinetics also increases the risk of falls 
through increased likelihood of ADR (American Psychology Association, 1998; 
Hamilton, Gallagher, Ryan, Byrne, O'Mahony, 2011).  Pharmacokinetics involves the 
effect the body has on medications including absorption, distribution, metabolism, and 
excretion (Brouwer & Olney, 2004; Shahezwan, Wahab, Nyfort-Hansen, Kowalski,  
2012).  Absorption of medications becomes slowed with advancing age.  Distribution of 
medications is affected by sarcopenia.  Sarcopenia is the normal, age related loss of 
muscle mass and strength and is one of the biggest indicators of functional ability 
(Brouwer & Olney, 2004).  Metabolism and excretion of medications is affected by the 
normal, age related decrease in renal and hepatic function (Williams, 2002).    
 Healthcare providers often struggle to find a balance between over prescribing 
and under prescribing medications to treat or prevent disease in geriatric patients, 
especially because chronic diseases often require more than one medication for treatment 
(Patterson et al, 2012; Klotz, 2009; Williams, 2002).  In the U.S., prevention and 
 6 
treatment of disease are often achieved with pharmaceuticals, but with more medications 
comes the increased likelihood of an ADR (Werder & Preskorn, 2003; Perry 2008).  The 
U.S. General Accounting Office (1995) concluded that although, at that time, the geriatric 
population made up only about 15 percent of the U.S. population, they accounted for the 
purchase of 33 percent of prescription medications and 40 percent of over the counter 
medications.  
 The most commonly used over the counter mediations among geriatric patients, 
often used to treat OA are non-steroidal anti-inflammatory drugs (NSAIDs) (Page, 2000; 
Ejaz, Bhojani, Joshi, 2004; Yayla et al, 2013; Pretorius, Gataric, Swedlund, Miller, 2013; 
Berryman, Jennings, Ragsdale, Lofton, Huff, & Rooker, 2012).  NSAIDs increase 
systemic vascular resistance and can cause impaired renal perfusion leading to 
hypertension, congestive heart failure development or exacerbations, and kidney 
dysfunction (Page, 2000; Ejaz et al, 2004).  The use of NSAIDs is associated with an 
increased risk for gastrointestinal issues possibly leading to ulcers or bleeding, and 
central nervous system problems possibly leading to falls (Hegeman et al, 2009; Yayla et 
al, 2013).  
 Some of the other most common PIMs used in geriatric patients are long-term 
opiates, benzodiazepines, and antihistamines (Shahezwan et al, 2012; Beers, Ouslander, 
Rollingher, Reuben, Brooks, Beck, 1991; Beers, 1997; Fick, Cooper, Wade, Waller, 
Maclean, Beers, 2003; Ryan, O’Mahony, O’Donovan, O’Grady, Weedle, Kennedy, 
Byrne, 2012; American Pharmacists Association, 2012).  These medications can cause 
drowsiness, confusion, hypotension, bradycardia, and muscle weakness, increasing the 
risk of falls (Shahezwan et al,  2012).   Additionally, antihistamines can cause agitation, 
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hallucinations, delirium, and can contribute to cardiovascular disorders including 
dysrhythmias, prolonged QT intervals and postural hypotension in patients 65 years of 
age and older (American Pharmacists Association, 2012; Coggins, 2013).  
 For the reasons previously discussed, geriatric patients are more susceptible to 
PIM possibly leading to an ADR than younger patients (Gallagher et al, 2007; 
Shahezwan et al, 2012).   Geriatric patients with polypharmacy, more than five daily 
medications, have a one in three chance of experiencing an ADR as a result of an 
inappropriate medication and two thirds of those patients will need to seek medical care 
for that reaction.  Adverse drug reactions lead to increased healthcare utilization and cost 
(Gallagher et al, 2007).  In 2007, 12.9 million geriatric patients had at least one 
hospitalization as a result of an ADR lasting three to six days (Administration on Aging 
U.S. Department of Health and Human Services, 2011). Ninety five percent of those 
ADRs are predictable and 28 percent are preventable (Pham & Dickman, 2007). The 
most common ADR include falls, hip fractures, delirium, and urticaria all possibly 
leading to increased healthcare costs, decreased functional ability, and decreased quality 
of life (Pham & Dickman, 2007).  
 Consideration of the normal physiologic changes of aging, recalling knowledge of 
pharmacology and realizing the possibility for patient harm could be helpful in 
preventing PIM.  Inappropriate medications may also be prevented with regular 
medication reviews using a screening tool for guidance.  Medication reviews are 
recommended whenever a patient is seen for the first time, every six to 12 months, and 
whenever a new medication is being considered or prescribed (Pham & Dickman, 2007; 
Ryan, 2012). Medication reviews may be helpful in promoting the aggressive treatment 
 8 
of disease and minimizing the potential for ADR (Cahir et al, 2010; Steinman, 2007).  
 There are two different kinds of medication review processes including implicit 
measures and explicit measures.  Implicit measures allow providers to use their clinical 
judgement to determine what is appropriate for each patient on an individual basis.  
Explicit measures are based on guidelines and criteria developed by expert panels and 
consensus opinion that should be generalizable to all patients in all situations (Cahir et al, 
2010).  There are several explicit screening tools available for providers to utilize when 
conducting a medication review or considering prescribing a new medication for a 
geriatric patient.  
Beers Criteria 
 The most popular explicit medication screening tool used in the U.S. and 
currently recommended by the American Geriatrics Society, National Committee for 
Quality Assurance, Pharmacy Quality Alliance, and Centers for Medicare and Medicaid 
Services is the Beers Criteria developed by Mark Beers M.D. and an expert consensus 
panel in 1991 and updated in 1997, 2003, and 2012 (Cahir et al, 2010; O’Mahony, 
Gallagher, Byrne, Hamilton, Barry, O’Connor, Kennedy, 2010; Vishwas, Harugeri, 
Parthasarathi, Ramesh, 2012; Ryan, O’Mahony, Kennedy, Weedle, Byrne, 2009; Pham & 
Dickman, 2007; Shahezwan et al, 2012; Ramaswamy et al, 2010; Fick & Semla, 2012; 
Resnick & Pacala, 2012; Cherubini, Corsonello, Lattanzio, 2012; Vieira de Lima, Garbin, 
Garbin, Sumida, Saliba, 2013; Gillespie, Alassaad, Hammarlund-Udenaes, Morlin, 
Henrohn, Bertilsson, Melhus, 2013).  The American Geriatric Society recommends that 
the Beers Criteria will be updated every three years to remain current (Marcum & 
Hanlon, 2012; Campanelli, 2012).  The 2012 updated Beers Criteria is made up of 53 
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medications divided into three sections including 1) PIM and classes to avoid in geriatric 
patients independent of diagnosis, 2) PIM and classes to avoid considering certain disease 
processes in geriatric patients, and 3) medications to use with caution in geriatric patients 
(American Geriatric Society, 2012). 
 In 2012, an expert consensus panel updated Beers Criteria by removing 
medications no longer available, adding medications new to the market since 2003, 
updating the list of common geriatric diseases, adding a list of medications to use with 
caution, and adding new research (Gallagher et al, 2007; Ryan et al, 2009; Pham & 
Dickman, 2007; Fick & Semla, 2012;  Resnick & Pacala, 2012).   With the addition of 
new research, a rating of the quality and strength of the evidence and recommendation is 
given for each medication, regardless of whether it is classified by drug category or 
disease process (American Geriatric Society, 2012; Resnick & Pacala). The expert 
consensus panel emphasizes the Beers Criteria should never replace clinical judgement, 
but rather serve as a reminder to closely monitor or avoid, if possible, certain medications 
in the geriatric population (Resnick & Pacala, 2012; Campanelli, 2012).  As a reminder 
for clinical practice, Fick and Semla (2012) propose the updated criteria could be easily 
implemented into an electronic medical record and provide prompts and possibly 
alternative interventions when a PIM has been identified.   
 The Beers Criteria has been examined extensively in research since its 
development and found to be effective in identifying PIM and advising close monitoring 
of certain medications (Gillespie et al, 2013).  However, evidence supporting the 
effectiveness of the Beers Criteria in consistently reducing ADR or decreasing cost or 
mortality is lacking (Spinewine, Schmader, Barber, Hughes, Lapane, Swine, Hanlon, 
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2007; Jano & Aparasu 2007; Resnick & Pacala, 2012; Pham & Dickman, 2007). The 
Beers Criteria does not take into account geriatric patients in palliative care or hospice, 
does not detect prescribing omissions, underuse of medications, drug to drug interactions, 
inappropriate dosing of medications, or duplication of drug classes (Shahezwan et al, 
2012: Barry et al, 2007; Gallagher et al, 2007; Fick & Semla, 2012).    
STOPP Criteria 
 A newer physiological systems based explicit screening tool is the 
STOPP/START Criteria, developed in Europe in 2003, and validated with a Delphi 
consensus for use in 2006 (Gallagher et al, 2007).  The STOPP/START Criteria is used to 
detect PIM being prescribed and to identify PPO.  Eighteen experts in Geriatric 
Pharmacotherapy from Ireland and the United Kingdom participated in two rounds of the 
Delphi validation process (Gallagher et al, 2009; Dalleur et al, 2012; Gallagher et al, 
2007; Yayla, Bilge, Binen, Keskin; 2013). The criteria, last updated in 2006, are broken 
down by body system, take into account specific patient information, and are separated 
into a list of PIM to STOPP and a list of PPO to START.   The STOPP/START Criteria 
are supported by the European Union of Geriatric Medicine Society (EUGMS) and was 
slated for an updated validated version in late 2012 or early 2013 (Marcum & Hanlon, 
2012).  The criteria is helpful in completing medication reviews because it considers the 
patients diagnosis and past medical history, PIM, PPO, duplicate drug classes, duration of 
treatment errors, and medications likely to cause a fall (Shahezwan et al, 2012; Gallagher 
et al, 2009; Barry, Gallagher, Ryan, O’Mahony, 2007; Gallagher et al, 2007). 
 The STOPP Criteria contains 65 evidence based indicators for potentially 
inappropriate prescribing with an explanation for why the medication could be 
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inappropriate in a geriatric patient appearing next to each criteria (Gallagher et al, 2009; 
Dalleur et al, 2012; Gallagher et al, 2007; Onatade, Auyeung, Scutt, Fernando, 2013).  
The STOPP Criteria can be used as a medication screening tool effectively even without 
a patient’s past medical history or other clinical information (Ryan et al, 2012).   It is 
believed to be comprehensive and time efficient (Gallagher et al, 2007).  The STOPP 
Criteria takes approximately three minutes per patient to use and could readily be 
incorporated into an electronic medical system for easier application (Gallagher, 
O’Connor, O’Mahony, 2011; Ryan et al, 2009; Gallagher et al, 2009; Dalleur et al, 2012). 
START Criteria 
 The START Criteria contains 22 evidence based indicators for prescribing 
omissions with an explanation for why the medication could be indicated in a geriatric 
patient appearing next to each criteria (Gallagher et al, 2009; Dalleur et al, 2012).  The 
most effective method to apply this criteria as a medication screening tool is to have a 
patient’s past medical history and other clinical information available (Ryan et al, 2012).  
Physicians may be cautious to prescribe medications to geriatric patients out of fear 
related to multiple co-morbidities, fear of polypharmacy, economic reasons, or ageism 
(Cherubini, Corsonello, Lattanzio, 2012).  However, this criteria has compiled a list of 
medications that are indicated to prevent or treat disease and can be applied in one minute 
(Cherubini, 2012; Beer, Hyde, Almeida, 2011; Gallagher, O’Connor, O’Mahony, 2011; 
Ryan et al, 2009; Gallagher et al, 2009).   
 Review of current literature revealed the two most common prescription 
omissions were Calcium and Vitamin D supplements in OP and high fall risk men and 
women (Sloane, Gruber-Baldini, Zimmerman, Roth, Watson, Boustant, 2004; Rosen, 
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Karter, Liu, Selby, Schneider, 2004; Kiebzak, Beinart, Perser, Ambrose, Siff, Heggeness, 
2002; Trivedi, Doll, Khaw, 2003). Prevention and treatment of OP may be improved in 
older adults with simple treatments like an appropriate single monthly dose of Calcium 
and Vitamin D (Kiebazk, 2002; Trivedi, Doll, Khaw, 2003). Bisphosphonates are also 
indicated for the treatment of OP and have been shown effective in preventing fractures 
(Whitaker, Guo, Kehoe, Benson, 2012).   
 The goal for the use of a medication screening tool in practice is to allow 
prescribers to use their expertise and clinical judgement in a timely manner as the tool 
should be evidence-based, simple to use, and work well with an electronic medical record 
(O’Mahony et al, 2008). There are several concerns expressed with both criteria.  
Concerns with the Beers Criteria include poor organization, inefficiency, missing 
medications and interactions, and duplicate medications and prescribing omissions are 
not addressed (Ryan et al, 2009; O’Mahony, 2012; Cahir et al, 2010; O’Mahony et al, 
2010; Shahezwan et al, 2012; Fisk & Semla, 2012; Barry et al, 2007; Campanelli, 2012).  
Concerns with the STOPP/START Criteria include that existing research are reviews 
rather than clinical studies, the last update was seven years ago, and there is a lack of 
research conducted with the criteria in the United States (Bradley, Fahey, Cahir, Bennett, 
O’Reilly, Parsons, and Hughes, 2012; Yayla et al; 2013; O’Mahony et al, 2010).  The 
Beers Criteria has been studied extensively in the U.S. and the STOPP/START Criteria 
has been studied in a variety of settings across Europe; but minimally in the U.S. (Cahir 
et al, 2010; O’Mahony, Gallagher, Byrne, Hamilton, Barry, O’Connor, Kennedy, 2010; 
Vishwas, Harugeri, Parthasarathi, Ramesh, 2012; Ryan, O’Mahony, Kennedy, Weedle, 
Byrne, 2009; Pham & Dickman, 2007; Shahezwan et al, 2012; Ramaswamy et al, 2010; 
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Fick & Semla, 2012; Resnick & Pacala, 2012; Gallagher et al 2008; Lang Hasso, Belmin, 
Payot, Baeyens, Vogt-Ferrier, Gallagher, O'Mahony, Michel, 2009, Cherubini et al, 2012; 
Ubeda, Ferrandiz, Maicas, Gomez, Bonet, Peris, 2012, Windsant-van den Tweel, 
Windsant-van den Tweel, Verduijn, Derijks, van Marum, 2012).   
 There are many similarities between the Beers Criteria and the STOPP/START 
Criteria, therefore, studies have been conducted in Europe to compare the two criteria.  
The Beer’s Criteria has a disadvantage in European studies versus the STOPP/START 
Criteria because some of the medications that appear on the Beers Criteria are not 
available in Europe (Yayla et al, 2013). Overlooking this disadvantage, European 
research suggests STOPP Criteria may be more sensitive and possibly more effective 
than the Beers Criteria at identifying PIM and preventing ADRs.  This increased 
sensitivity may be attributed to the 33 PIM that appear on the STOPP Criteria that are not 
present on the Beers Criteria (Gallagher et al, 2007; Gallagher, O’Mahony, 2008; 
Hamilton et al, 2011; O’Mahony et al, 2010; Ryan et al, 2009).    
 Hamilton and colleagues (2011) found in 151 potentially avoidable ADR that led 
to hospitalization in Ireland, 94 were found in the STOPP Criteria compared to 34 
identified by the Beers Criteria.  Ryan and colleagues (2009) found in Irish primary care 
that the Beers Criteria identified PIM in 18.3 percent of patients, STOPP Criteria 
identified PIM in 21.4 percent, and START Criteria identified PPO in 22.7 percent of 
patients.  Gallagher and colleagues (2011) determined that appropriate prescribing is 
significantly improved after correct and rigorous application of STOPP/START, even if 
only applied one time.  Gallagher and colleagues (2008) found a significant difference in 
the detection of PIM.  Hill-Taylor and colleagues (2013) conducted a systematic review 
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and determined the STOPP/START Criteria may be more sensitive than the 2003 version 
of the Beers Criteria.  
 The previous studies were conducted in European settings.  Few studies have 
examined the STOPP/START Criteria in the U.S.,  Brahmbhatt and colleagues (2013) 
applied the STOPP/START Criteria in the U.S. and found a significant decrease in the 
number of medications triggered as inappropriate after initial and follow-up application 
of the criteria. With the limited research conducted in the U.S., especially in comparing 
the STOPP/START Criteria and the Beers Criteria additional research needs to be 
conducted in the U.S. to determine which criteria is more appropriate or effective in 
minimizing inappropriate medications and ADRs. 
Theoretical Framework  
  Inappropriate medications increase the likelihood of ADR.  Adverse drug 
reactions include a negative reaction to pharmacotherapy including confusion, 
depression, constipation, falls, fractures, delirium, possible hospitalization, and mortality 
(Cahir et al, 2010; Shahezwan, 2012; Hamilton, 2009; Brahmbhatt, Palla, Kossifologos, 
Mitchell, and Lee, 2013; Pretorius et al, 2013).   Potentially inappropriate medications 
may be detected with a medication review (Hamilton, Gallagher, O’Mahony, 2009; 
O’Sullivan, O’Mahony, Parsons, Murphy, Patterson, Byrne, 2013).  A medication review 
is a structured examination that involves identifying all current prescription, over-the-
counter, and complementary medications an individual is taking in an attempt to agree 
about their treatment, decrease cost, and prevent or minimize inappropriate medications 
(NHS Cumbria Medicines Management Team, 2013; Pretorius et al, 2013).   
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 Medication reviews should be conducted when a patient is seen for the first time, 
every six months or annually, when a new medication is prescribed, or when there is a 
transition of care (Feinberg and Simonson, 2005, Barnsteiner, 2008; Pham & Dickman, 
2007; Ryan 2012).  More than 40 percent of PIM are present because medication reviews 
were not conducted during a transition of care (Barnsteiner, 2008).  Critical review of 
medication lists in geriatric patients often results in change (Cockburn, 1997; Taziaux, 
Franck, Ludovicy, Albert, 1996).  Therefore, if a medication review tool is regularly 
utilized to assess medication lists, some PIM may be discontinued and some PPO may be 
initiated resulting in improved patient safety and decreased morbidity (Hamilton et al, 
2009, O’Sullivan et al, 2013; Hill-Taylor, Sketris, Hayden, Byrne, O’Sullivan, Christie, 
2013).  
  Patient safety is the goal of healthcare providers and the organizations in which 
they function.  Medication screening tools may be a simple and effective means to 
promote and achieve the goal of increased patient safety by screening for PIM or PPO. 
Effectiveness of a medication review depends on the environment, including how much 
time the provider is able to spend with a patient, the thoroughness of the reported 
medication list, and a familiarity with the patient’s medical and social history.   
Scott’s Adaptation of Leavitt’s Diamond 
Leavitt’s Diamond is an organization model created by Harold J. Leavitt in 1965 
(Bloomsbury Business Library, 2007).  Leavitt created a diamond shaped visual as a way 
to understand the model that an organization exists within its environment and does not 
experience change in isolation, but rather as change occurs to one part of the diamond it 
will impact every other part (Bloomsbury Business Library, 2007).    In 1998, W. Richard 
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Scott, a sociology professor at Stanford University, adapted Leavitt’s original diamond. 
The four corners of Scott’s adaptation of Leavitt’s diamond include 1) technology, 2) 
participants, 3) social structure, and 4) goals (Wilson, 1995; Roberts, Hopp, Sorensen, 
Benrimoj, Chen, Herborg, Williams, and Aslani, 2003).  Scott’s adaptation of Leavitt’s 
Diamond serves as the theoretical framework for this study. 
 
Conceptual and Operational Definitions 
 In Scott’s model the entire organization exists within an environment and all the 
parts work together.  The 1) technology refers not only to the computers and machines 
used within the organization but also the protocols, guidelines, and resources that are 
used to promote quality and achieve goals. The 2) participants are the people involved in 
the organization. The 3) social structure is the culture or relationship the participants have 
 Organization 
Environment 
 
Technology Goals 
Participants 
 
 
(Roberts, Hopp, 
Sorensen, Benrimoj, 
Chen, Herborg, 
Williams, and Aslani, 
2003) 
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with the organization and could include the way participants interact with one another, 
financial resources, the physical environment the organization exists within, etc.  The 4) 
goals are the outcomes the participants and organization are trying to achieve.  The goals 
of an organization must be the same for all participants for true success to be achieved.  
The strength and success of the entire organization relies on the knowledge, skills, and 
dedication of the participants.   Every part of the diamond affects the others and requires 
the others to function (Wilson, 1995; Roberts et al, 2003).   
 The present study is examining the 1) technology corner, the 2) participants 
corner, and the 3) social structure corner of the Scott’s model.  The 1) technology for this 
study is operationally defined as medication screening tools specifically, sections of the 
Beers Criteria and the STOPP/START Criteria.    The 2) participants for this study are 
patient medical records and the 3) social structure is the setting of a musculoskeletal 
specialty practice.   
 Potentially inappropriate medications are those that pose a greater risk than 
benefit for the patient (Shahezwan, 2012; Gallagher, Baeyens, Topinkova, Madlova, 
Cherbuini, Gasperini, Cruze-Jentoft, Monero, Lang, Michel, O’Mahony, 2009; Gallagher, 
Ryan, Byrne, Kennedy, O’Mahony, 2007; O’Mahony et al, 2008; Ramaswamy et al, 
2010; Parsons, Johnston, Mathie, Baron, Machen, Amador, Goodman, 2012).  This 
encompasses polypharmacy, medication duplication, PPO, dosage errors, duration of 
treatment errors, and prescribing cascades (Gallagher et al, 2007; Shahezwan et al, 2012).  
Polypharmacy does not have a consensus definition in literature but many studies cite 
five or more medications as a common occurance and the point at which patients become 
more likely to experience an ADR (Pham & Dickman, 2007; Williams, 2002; Olsson, 
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Runnamo, Engfeldt, 2011; Dovjak, 2012).  For the purpose of this study, polypharmacy 
means taking five or more medications (Kaufman, Kelly, Rosenberg, Anderson, Mitchell, 
2002; Pham & Dickman, 2007).  Medication duplication occurs when multiple drugs 
from the same class are being taken.  Dosage errors occur when a medication is being 
taken at a dose with higher or lower than what is indicated for treatment.  Duration of 
treatment errors include a medication being taken for either too many or too few days.  
Prescribing cascades include when a patient develops an unexpected side effect from one 
medication that is mistaken as another disease process and requires treatment from 
another medication (Rochon & Gurwitz, 1997).  Potential medication omissions occur 
when a medication indicated for treatment is not being taken (Cherubini et al, 2012).   
 In the U.S. the Beers Criteria has been used extensively to identify PIM in the 
geriatric population.  Currently there is not enough research evidence to make a 
recommendation for prescribers in the U.S. to use the STOPP/START to identify PIM.  
There is a need to apply both the STOPP/START and the Beers Criteria to the same 
geriatric population in a U.S. setting to describe and compare their application. A 
musculoskeletal specialty setting in the midwest was selected as an ideal setting due to 
the ability to review the medical records of geriatric patients who suffer from chronic 
conditions including OA, OP, falls, and fractures.   
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Chapter Three: Methodology 
Research Design 
 The research design for this study was a retrospective descriptive, comparative 
design.  A chart review was completed for the purpose of describing and comparing the 
appropriateness of the Beers Criteria versus the STOPP/START Criteria in identifying 
PIM or PPO in a U.S. setting.  
Criteria Validity 
 The Beers Criteria content validity was established in 1991.  Validity was 
established using two rounds of Delphi consensus methodology with a panel of 13 
experts.   Most recently in 2012 the American Geriatric Society sponsored 11 experts to 
update and revise the 2003 Beers Criteria (Marcum & Hanlon, 2012).   
 The STOPP/START Criteria’s content validity was established using two rounds 
of Delphi consensus methodology in 2003 and 2006.  A panel of 18 experts in geriatric 
medicine, pharmacotherapy, old age psychiatry, and primary from Ireland and UK 
collaborated to establish the final STOPP/START Criteria.  The final STOPP Criteria 
contains 65 of the original proposed 68 criteria and all 22 of the original START Criteria 
(O’Mahony et al, 2009).  The criteria has strong inter-rater reliability with a kappa 
coefficient for STOPP 0.88 and START 0.90 among pharmacists and STOPP 0.75 and 
START 0.68 among physicians (Ryan et al, 2009; Gallagher et al, 2009).   
Setting 
 The setting of this study was a musculoskeletal specialty practice in the Midwest.  
This setting offered a large volume of geriatric patients with risk for falls, fractures, and 
musculoskeletal conditions including OA and OP.    
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Participants 
 The participants of this study were a convenient sample of patient medical records 
from a musculoskeletal specialty practice. The sample size for this study was 60 medical 
records.     
 Inclusion criteria included both males and females, of all races and ethnicities.  
Participants were all 65 years of age or older, seen at the practice within a six month 
period (December 2012-May 2013), and took at least one prescription medication on a 
regular basis.  Participants had at least one of the following diagnoses which are included 
in the STOPP/START Criteria: OA, OP, gout, atrial fibrillation, hypertension, congestive 
heart failure, peptic ulcer disease, gastrointestinal bleed, renal failure, Parkinson’s, 
chronic pain, anxiety, depression, insomnia, or seasonal allergies. Exclusion criteria 
included nursing home residents, because they are not living in the community and those 
with diagnosed terminal illnesses because neither criteria is based on care of terminal 
patients.   
Data Collection  
  Data was collected in July 2013 from an electronic charting system.  1) Records 
were accessed electronically by one researcher.   2) Selection began by electronically 
identifying the records of patients seen during a six month period (December 2012-May 
2013).  3) Records were then assessed for inclusion and exclusion criteria, specifically 
past medical history, up to a convenient sample of 63 participants.  Based on expected 
attrition, three charts were added to the calculated sample size of 60.  4) The charts were 
then coded one through 63 to ensure patient privacy.  5) Once 63 records were found that 
met inclusion criteria, demographic data was collected as available (Appendix C).  5) The 
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a. STOPP Central Nervous System & Psychotropic Drugs, b. STOPP Musculoskeletal 
System Drugs, c. STOPP Drugs that Adversely Affect those Prone to Falls, and d. 
STOPP Analgesic Drugs (Appendix A) were applied to each medical record.  6) The 
START Musculoskeletal System Criteria (Appendix A) was applied to each medical 
record.  7)  The Beers Criteria PIM to avoid by therapeutic category a. Antihistamines, b. 
Pain Medications, and PIM to avoid by disease/syndrome c. History of Falls or Fractures, 
d. History of Gastric Ulcer and Duodenal Ulcers, e. Chronic Kidney Disease were applied 
to each medical record. The application of each criteria to each individual medical record 
was timed.  8) Confidentiality and privacy were ensured with a systematic approach, only 
identifying the patients by one through 63, and keeping collected information locked.  
Data Analysis 
 Data was analyzed on SPSS version 21.0 (IBM corp, 2012).  The demographic 
and past medical history characteristics of the sample were identified using descriptive 
statistics reported as percentages, frequencies, means, and standard deviations.  1) Rate of 
PIM identified by specific sections of the Beers Criteria (Appendix B) and specific 
sections of the STOPP Criteria (Appendix A), 2) Rate of PPO identified by a specific 
section of the START Criteria (Appendix A), 3) most common PIM or PPO drug classes 
identified by each criteria, and those 4) identified with polypharmacy, and 5) length of 
time for application of each criteria was also identified using descriptive were identified 
using descriptive statistics reported as percentages, frequencies, means, and standard 
deviations.  
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Ethical Considerations 
 Approval from the Institutional Review Board at Cedarville University and the 
musculoskeletal specialty practice was obtained in June 2013.  Due to the nature of this 
retrospective study design, the researcher had no contact with the individual patient, and 
no patient harm was anticipated.  An ethical consideration was protecting patient’s health 
information.  To protect patient’s privacy, the only data collected was information that 
appeared on the approved demographic collection tool and the two criteria.  No patient 
identifiers were collected, patients were identified from one to 63.   
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Chapter 4: Results 
 
Sample Characteristics 
 A total of 63 medical records were identified and included in this retrospective 
descriptive, comparative chart review.  Table one summarizes the demographic 
characteristics of the sample.  The mean age of patients was 74 + 7.2 years, 95.2% were 
Caucasian, and 60.3% were females.  The total number of medications prescribed was 
468, with a range of 1-25 medications per patient and a mean of 7.43 medications per 
patient.  The most common chronic disease identified was OA in 98.4% of the sample.   
Table 1 
Demographic Data 
Characteristic  No. (%) Mean (SD) Range 
Male 25 (39.7)   
Age  74.68(+7.2) 65-95 
Race 
Caucasian 
African American 
Asian/Pacific Islander 
60 (95.2) 
2 (3.2) 
1 (1.6) 
  
Insurance 
Private 
Medicare 
Medicare with Secondary Carrier 
8 (12.7) 
26 (41.3) 
29 (46) 
  
Hospitalizations in the last year 4 (6.3)   
Falls in the last 3 months 3 (4.8)   
Most common Chronic Diseases 
Osteoarthritis 
Hypertension 
Hyperlipidemia 
Hypothyroidism 
Depression 
Osteoporosis 
 
62 (98.4) 
49 (77.8) 
27 (42.9) 
12 (19) 
11 (17.5) 
10 (15.9) 
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Rates of PIM 
Beers Criteria results.  Table two summarizes PIM identified by sections of both 
the Beers and the STOPP Criteria.  After applying the Beers Criteria, a total of 32 PIM 
were identified in 39.7% of medical records, with 72% of PIM being prescribed to 
females.  Twenty two (68.8%) medical records with PIM had one medication identified 
and five (31.3%) medical records with PIM had two medications identified.    
STOPP Criteria results.  After applying the STOPP Criteria a total of 67 PIM 
were identified in 58.7% of medical records.   Females were prescribed 67.6% of PIM.  
Seventeen (25.4%) medical records with PIM identified one medication, 13 (38.8%) 
medical records with PIM identified two medications, five (22.4%) medical records with 
PIM identified three medications, one (6%) medical record with PIM identified four 
medications, and one (7.5%) medical record with PIM identified five medications.  
Table 2 
PIM Identified by the Beers & STOPP Criteria 
 Beers Criteria  STOPP Criteria 
No. of PIM No. (%)  No. (%) 
1 22 (68.8)  18 (25.4) 
2 5 (31.3)  13 (38.8) 
3   5 (22.4) 
4   1 (6.0) 
5   1 (7.5) 
Total no. of PIM 32  67 
    
No. Males with PIM 7 (28)  12 (32.4) 
No. Females with PIM 18 (39.7)  25 (67.6) 
Total no. of individuals with 
PIM identified 
25 (39.7)  37 (58.7) 
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Rates of PPO 
START Criteria results.  Table three summarizes the PPO identified by the 
musculoskeletal section of the START Criteria.  After applying the START Criteria a 
total of 16 PPO were identified in 11 individuals, 63.6% of PIM were prescribed to 
females.  Six (37.5%) medical records with PPO had one medication identified, five 
(62.5) medical records with PPO had two medications identified.  Omission of Calcium 
supplements accounted for 37.5% of all PPO and omission of Vitamin D accounted for 
31.3% of all PPO (Table 3).  The mean age of those identified with a PPO was 78.5 years 
while the mean age of those without PPO identified was 73.9 years. 
Table 3 
PPO identified by START Criteria 
 START Criteria 
No. of PPO No. (%) 
1 6 (37.5) 
2 5 (62.5) 
Total no. of PPO 16 
  
No. of Males with PPO 4 (36.4) 
No. of Females with PPO 7 (63.3) 
Total no. of individuals with PPO 11 (17.5) 
 
 
PIM and PPO Identified by Class 
 
 PIM classes identified by Beers Criteria. Table four summarizes the most 
frequent classes of PIM identified by sections of the Beers Criteria.  The prescription of 
NSAIDS, excluding aspirin (ASA), accounted for 68.8% of PIM identified by the criteria, 
specifically the section independent of diagnosis.  The prescription of benzodiazepines in 
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patients with a history of falls accounted for 3.1% of PIM identified, and was the only 
medication class identified by the Beers Criteria section that considers diagnosis.    
Table 4 
PIM Classes: Beers Criteria 
Medication Total No. (%) 
Drug Class (Independent of Diagnosis) 
First Generation Antihistamines 
NSAID (excluding ASA) 
Skeletal Muscle Relaxants 
 
6 (18.8) 
22 (68.8) 
3 (9.4) 
Drug Class (Considering Diagnosis) 
Benzodiazepines with history of fall 1 (3.1) 
Total no. of PIM 32 
 
 
 PIM classes identified by STOPP Criteria.  Table five summarizes the most 
frequent classes of PIM identified by the applied sections of the STOPP Criteria.  The 
long-term use of NSAIDs to treat OA accounted for 49.3% of PIM and long-term opiate 
use to treat mild to moderate pain accounted for 26.9% of PIM identified by the STOPP 
Criteria.  Some medical records triggered PIM in multiple sections of the STOPP Criteria 
for several medication classes including, NSAIDs, benzodiazepines, opiates, and first 
generation antihistamines.  Those medications were only counted as one PIM, because 
the different sections identified one PIM, several different times (Table 5*).  There were, 
however, several medical records that had more than one medication from a drug class 
listed, including NSAIDs and opiates, and those medications were counted separately and 
included in the total PIM. 
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Table 5  
 
PIM Classes: STOPP Criteria 
 
Medication Total No. (%) 
CNS & Musculoskeletal System 
Long-term Benzodiazepines 
Prolonged use of 1
st
 Generation Antihistamines 
 
8 (11.9) 
6 (8.9) 
Musculoskeletal System 
NSAID with moderate-severe Hypertension 
NSAID with Heart Failure 
Long-term NSAID use to treat OA 
Long-term Corticosteroid use to treat OA or Rheumatoid 
Arthritis (RA) 
3 (4.5) 
1 (1.5) 
29 (43.3) 
 
2 (2.9) 
Drugs that Adversely Affect Fallers 
Benzodiazepines 
1
st
 Generation Antihistamines 
 
1* 
1* 
Analgesic Drugs 
Long-term Opiates to treat mild-moderate pain 
 
18 (26.9) 
Total no. of PIM 67 
 
*not included in total count of PIM, already identified & counted as PIM in a previous section of criteria 
 
 PPO classes identified by START Criteria.  Table six summarizes the most 
frequent classes of PPO identified by the START Criteria musculoskeletal section.  The 
most common potential prescription omissions identified were Calcium and Vitamin D.  
Omission of Calcium supplements accounted for 37.5% of all PPO and omission of 
Vitamin D accounted for 31.3% of all PPO. 
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Table 6  
 
PPO Classes: START Criteria 
  
Medication START Criteria 
Musculoskeletal System 
DMARD with RA 
Bisphosphonates 
Calcium Supplement 
Vitamin D Supplement 
 
1 (6.2) 
4 (25) 
6 (37.5) 
5 (31.3) 
Total no. of PPO 16 
 
 
Polypharmacy 
 
Table seven summarizes the percentage of the sample with polypharmacy.  
Polypharmacy was identified in 73.02% of medical records. Patients were taking an 
average of 7.4 medications.    Table eight summarizes the average number of medications 
per age range.  The age range between 85-89 years had the highest average number of 
mediations per patient (9.8); however, there were only four medical records included in 
this age range.  The largest number of medical records, (25 records, 37.3%) were in the 
age range of 70-74 years of age.   
Table 7 
Patients Experiencing Polypharmacy 
 
Characteristic  No. (%) SD Range 
Total no. of Drugs Prescribed 468   
Mean no. of Drugs Prescribed per Patient 7.4 +4.7 1-25 
No. of patients with Polypharmacy (>5 Drugs) 46 (73) 4.4  
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Table 8 
 
Mean Medications Prescribed per Age Range 
Length of Time 
 
 Table nine summarizes the length of time for the application of each criteria.  The 
sections of the Beers Criteria that were applied took a mean time of 17.38 seconds a 
medical record. The sections of the STOPP Criteria that were applied took a mean time of 
20.15 seconds a medical record. The section of the START Criteria applied took a mean 
time of 4.02 seconds a medical record. 
Table 9 
 
Length of Time for Application per Criteria 
 
 Beers Criteria   STOPP Criteria  START Criteria 
Variable Mean SD Range  Mean SD Range  Mean SD Range 
Mean time 
in seconds 
17.4 +7.1 8-46 
 
20.2 +8.9 8-53 
 
4 +1.7 2-10 
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Chapter 5: Summary 
  
Discussion Overview 
 This study showed that the use of medication screening tools, specifically sections 
of both the Beers and STOPP/START Criteria, identified PIM and PPOs with a 
retrospective chart review.  There is little to no research conducted with the application of 
only selected sections of both criteria, specifically in a musculoskeletal practice, 
therefore, the results of this study are somewhat unique.  Several European studies 
conducted in a variety of settings have compared the application of the entire Beers and 
STOPP/START Criteria and the rate of PIM.  Due to the similar content of other studies 
and the present study, results can be compared while being mindful the differences in 
methodology and design.   
Discussion of Sample Characteristics  
 Considering the setting for data collection, it was anticipated that there would be a  
high incidence of musculoskeletal conditions including OA, OP, falls, and fractures.  
There was a high incidence, as expected, of OA with all but one medical record having a 
documented past medical history of OA.  It was surprising there was not a higher 
incidence of OP, with only 15.9% of the medical records reported OP in the past medical 
history.   The reason for this low incidence is unknown.  Additionally, the low incidence 
of hospitalizations or falls reported in patients was surprising.  Hospitalizations have been 
linked as a possible ADR caused by PIM (Yayla et al, 2013).  The ability to detect PIM 
may have been hindered with the low rates of reported hospitalizations and falls.    The 
sections of criteria related to patients with a history of falls were not applied to the 
medical records that did not report a recent fall. If a patient had a fall that was not 
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documented or reported, they could be at an unknown risk for PIM that is not being 
assessed.       
Discussion of Rates of PIM 
  Based on review of current literature it was anticipated the STOPP Criteria would 
identify more PIM than the Beers Criteria. Ryan and colleagues (2009) reported in a 
study conducted in an Irish primary care setting that the Beers Criteria identified PIM in 
18.3% of patients and the STOPP Criteria identified PIM in 21.4% of patients.  Gallagher 
and O’Mahony (2008) reported in an Irish acute care setting that the Beers Criteria 
identified PIM in 25% of patients while the STOPP Criteria identified PIM in 35% of 
patients.  Ubeda and colleagues (2012) conducted a study in long-term care facilities in 
Spain comparing the Beers and STOPP/START Criteria and reported the Beers Criteria 
identified PIM in 25% while STOPP identified PIM in 48% of patients.  A study done by 
Vishwas and colleagues (2012) reported different results from previously mentioned 
studies stating the Beers Criteria identified PIM in 24.6% of patients and STOPP only 
identified PIM in 13.3%.  The present study results show the rate of PIM identified in a 
musculoskeletal specialty practice in the Midwest applying specific sections of the Beers 
Criteria is 39.7% and specific sections of the STOPP Criteria is 58.7%.   
 The Beers and STOPP criteria have many similar PIM recommendations; 
however, there are several differences that may impact the number of PIM identified by 
each.   The organization of the criteria may impact the number of PIM identified.  The 
STOPP Criteria is organized by body system and considers specific patient clinical data, 
duplicate drug classes, and PPO while the Beers Criteria has 3 lists of medications to 1) 
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avoid considering diagnosis, 2) avoid independent of diagnosis, 3) use with caution and 
does not address PPO.   
 Both criteria overall identified NSAIDs, antihistamines, and benzodiazepines as 
PIM.  The Beers Criteria does not identify Aspirin >325mg daily to be to a potentially 
inappropriate NSAID or opiates to be PIM in the sections applied.  The STOPP Criteria 
does not consider skeletal muscle relaxants as a PIM in the sections applied.  A benefit to 
applying the STOPP Criteria is the patient specific information in each recommendation; 
however, this does bring some difficulty in a retrospective study.  One difficulty is in 
determining if OA being treated with NSAIDS is mild to moderate.  Based on review of 
current literature it was anticipated the STOPP Criteria would identify more PIM than the 
Beers Criteria. Ryan and colleagues (2009) reported in a study conducted in an Irish 
primary care setting that the Beers Criteria identified PIM in 18.3% of patients and the 
STOPP Criteria identified PIM in 21.4% of patients.  The results of the present study 
show the rate of PIM identified in a musculoskeletal specialty practice in the Midwest 
applying specific sections of the Beers Criteria is 39.7% and using sections of the STOPP 
Criteria is 58.7%.  These results are similar to the previously mentioned results of other 
studies in that the rate of PIM was higher with application of the STOPP Criteria than 
with the Beers Criteria. 
Discussion of rates of PPO 
  One benefit of applying the STOPP/START Criteria is the recognition of PPO by 
START, which the Beers Criteria does not consider.  Ryan and colleagues (2009) 
reported in a study conducted in an Irish primary care setting that PPOs were identified in 
22.7% of patients with a significantly higher incidence in females.  The results of the 
 33 
present study showed the rate of PPO identified in a musculoskeletal specialty practice in 
the Midwest using a section of the START Criteria was 17.5% and the incidence was 
higher in females (63.3%).  This result could be due, at least partially, because there were 
more females than males in the total sample.   
Discussion of PIM and PPO Identified by Class 
 Discussion of PIM classes identified by Beers Criteria.  Based on review of 
current literature Ryan and colleagues (2009) found that with the Beers Criteria, the 
identification of benzodiazepines accounted for 31.9% of PIM.  Ubeda and colleagues 
(2012) reported the two most commonly identified classes of PIM include NSAIDs and 
benzodiazepines.  According to the present study results the most common medication 
classes identified by the Beers Criteria were NSAIDs (68.8%).   
 Discussion of PIM classes identified by STOPP Criteria.  Based on review of 
current literature and basic knowledge about the musculoskeletal setting, the most 
anticipated classes of PIM included NSAIDs, opiates, and benzodiazepines. Dalleur and 
colleagues (2012) reported two of the most common PIM classes identified by the 
STOPP Criteria were benzodiazepines and opiates.  In an Australian hospital setting 
Shahezwan and colleagues (2012) reported the most common PIM identified by the 
STOPP criteria were long-term opiates and benzodiazepines prescribed to elderly patients 
with a history of falls.  Cahir and colleagues (2010) reported that the second and third 
most frequently reported PIM classes were, in order, NSAIDS for > 3 months and 
benzodiazepines.  According to the present study results the most common medication 
classes identified by the STOPP Criteria were long-term NSAID use to treat OA (43.3%), 
long-term opiates (26.9%), and long-term benzodiazepines (11.9%).    
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 Long-term NSAID use may be associated with gastrointestinal problems, heart 
failure exacerbation, and chronic renal failure (Cahir et al, 2013).  Benzodiazepine use in 
the geriatric population is associated with increased risk for falls, fractures, respiratory 
depression, impaired cognitive function, drowsiness, and dependence (Cahir et al, 2010; 
Shahezwan et al, 2012; Berryman et al, 2012).  Opiate use in the geriatric population can 
cause drowsiness, respiratory depression, hypotension, impaired balance leading to 
increased risk for falls and fractures (Shahezwan et al, 2012).   
 Discussion of PPO classes identified by START Criteria.  Dalleur and 
colleagues (2012) and Ubeda and colleagues (2012) found that the most common PPO in 
hospitalized elderly patients were the underuse of Calcium and Vitamin D 
supplementation.  According to the present study the most common PPO classes 
identified by the START Criteria were Calcium supplements (37.5%) and Vitamin D 
supplements (31.3%).  As previously mentioned,  there was a low incidence of patients 
with OP in this study.  This low incidence might negatively affect the identification of the 
PPO of bisphosphonates.  This could negatively impact patient outcomes considering, 
Dalleur and colleagues (2012) reported that fall-induced osteoporotic fractures were the 
most common hospital admission diagnosis related to inappropriate prescribing.   
Discussion of Polypharmacy 
 Due to the advanced age of the sample and multiple chronic diseases it was 
anticipated that a large number of patients would have polypharmacy.  According to the 
present study 46 patients (73%) had polypharmacy.  The mean number of drugs 
prescribed per patient was 7.4 medications with a range of 1-25 medications.  When 
considering the average number of medications per age range, it was anticipated that as 
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age increased, the average number of medications would also increase as was reported in 
a study conducted by Ryan and colleagues (2009).  In this study, however, this was not 
the case.  This unexpected finding could be a result of the unequal number of medical 
records in each age range (Table 8).  
Discussion of Application Length of Time 
 Only sections of each criteria were applied, for this reason it was difficult to 
predict the length of time for application of each criteria.  According to the present study 
the sections of the Beers Criteria took a mean time of 17.4 seconds to apply to a medical 
record, 2.8 seconds less on average than the sections of the STOPP Criteria.  The section 
of the START Criteria took an average of 4 seconds per medical record.  In current 
literature, no studies were found that compared the application time of the Beers Criteria 
and the STOPP/START Criteria in their entirety or sections.  Literature states that an 
individual familiar with the STOPP Criteria can apply it in its entirety in 3 minutes and 
the START criteria within 1 minute.  There is a short learning curve while one becomes 
familiar with the criteria (Gallagher et al, 2011). 
Limitations 
 There were several limitations to this study.  There is a lack of generalizability of 
results related to the small sample size and application in one specialty care practice in 
the Midwest.   Due to the retrospective design of the study there was a limited ability to 
consider prescribers opinions and clinical judgement.  Medications could have been 
identified as PIM that were clinically appropriate.  Application of only particular 
sections, rather than the entire STOPP/START Criteria or Beers Criteria is a potential 
limitation that may affect validity and reliability of the criteria.  However, based on the 
 36 
specialty practice where data was collected, a selection of criteria sections that match the 
specialty practice focus seemed appropriate for study.  The low incidence of documented 
hospital stays, recent falls, kidney function, and history of ulcers resulted in certain 
sections of both criteria not being applicable to medical records.  This may cause a false 
decrease in the number of PIM identified by each criteria.         
Implications for Practice 
 Descriptive statistics confirmed that sections of the STOPP Criteria identified 
more PIM than sections of the Beers Criteria in the same sample. However, at least in the 
sections applied the Beers Criteria may be faster to apply to a medical record.  The 
limitation of only applying sections of each criteria impacts the implications for practice 
because a provider would likely apply the entire criteria to a medical record.   
Recommendations for Future Research 
 Future research recommendations relating to the study of the Beers and 
STOPP/START Criteria include studies with larger sample sizes, a primary care setting 
in the U.S., and the application of both criteria in their entirety.  A different study design 
should be conducted to assist in the application of the criteria in conjunction with clinical 
judgement to see how the criteria function in practice.  Both criteria need regular updates 
to remain relevant for future study.  
Conclusion 
 In conclusion, the problem of avoiding PIM and preventing potential ADR in the 
geriatric population is complex.  However, prevention of PIM and potential ADR may be 
achieved with a medication screening tool.  Medication screening tools can assist with 
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education about PIM and a reminder to regularly evaluate medications prescribed to the 
geriatric population.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
References 
 
Administration on Aging U.S. Department of Health and Human Services (2011).  A 
profile of older americans: 2011.  Retrieved on March 27, 2013, from: 
http://www.aoa.gov/Aging_Statistics/Profile/2011/docs/2011profile.pdf. 
 
American Geriatric Society (2012).  American Geriatrics Society updated Beers Criteria 
for potentially inappropriate medication use in older adults.  Retrieved on April 4, 
2013, from: 
http://www.americangeriatrics.org/files/documents/beers/2012BeersCriteria_JAG
S.pdf. 
 
American Pharmacists Association (2012).  Nonprescription antihistamines: Geriatric 
considerations.  Retrieved July 14, 2013 from: 
http://www.pharmacist.com/nonprescription-antihistamines-geriatric-
considerations. 
 
American Psychology Association (1998).  Older adults’ health and age-related changes: 
Reality versus myth [Brochure].  Washington, DC: n.p. 
 
Barnsteiner, J. (2008). Medication reconciliation.  In R.G. Hughes (Ed.), Patient safety 
and quality: an evidence-based handbook for nurses.  Rockville (MD): Agency 
for Healthcare Research and Quality.   
 
Barry, P., Gallagher, P., Ryan, C., O’Mahony, D.  (2007).  START (screening tool to 
alert doctors to the right treatment) an evidence-based screening tool to detect 
prescribing omissions in elderly patients.  Age and Aging, 36, 632-638.   
 
Beer, C., Hyde, Z., Almeida, O. (2011).  Quality use of medicines and health outcomes 
amount a cohort of community dwelling older men: An observational study. 
British Journal of Clinical Pharmacology, 71(4), 592-599.  
 
Beers, M. (1997).  Explicit criteria for determining potentially inappropriate medication 
use by the elderly.  An update.  Archives of Internal Medicine, 157(14), 1531-
1536.   
 
Beers, M., Ouslander, J., Rollingher, I., Reuben, D., Brooks, J., Beck, J., (1991). Explicit 
criteria for determining inappropriate medication use in nursing home residents.  
UCLA Division of Geriatric Medicine, Archives of Internal Medicine, 151(9), 
1825-1832.   
 
Berryman, S., Jennings, J., Ragsdale, S., Lofton, T., Huff, D., Rooker, J., (2012).  Beers 
Criteria for potentially inappropriate medication use in older adults.  Med-Surg 
Nursing, 21(3), 129-133. 
 
Bloomsbury Business Library (2007).  Leavitt’s diamond.  A & C Black Publishers Ltd. 
 39 
 
Bradley, M., Fahey, T., Cahir, C., Bennett, K., O’Reilly, D., Parsons, C., Hughes, C. 
(2012).  Potentially inappropriate prescribing and cost outcomes for older people: 
A cross-sectional study using the northern Ireland enhanced prescribing database.  
European Journal of Clinical Pharmacology, DOI 10.1007/s00228-012-1249-y. 
 
Brahmbhatt, M., Palla, K., Kossifologos, A., Mitchell, D., Lee, T. (2013).  
Appropriateness of medication prescribing using the STOPP/START Criteria in 
veterans receiving home-based primary care.  The Consultant Pharmacist, 6(28), 
361-369.   
 
Brouwer, B., Olney, S. (2004).  Aging skeletal muscle and the impact of resistance 
exercise.  Physiotherapy Canada, 56(2), 80-87. 
 
Cahir, C., Fahey, T., Teeling, M., Teljeur, C., Feely, J., Bennett, K. (2010).  Potentially 
Inappropriate prescribing and cost outcomes for older people: A national 
population study.  British Journal of Clinical Pharmacology, 69(5), 543-552. 
 
Campanelli, C. (2012).  American Geriatric Society updated Beers Criteria for potentially 
inappropriate medication use in older adults.  Journal of the American Geriatric 
Society, 60(4), 616-631. 
 
Centers for Medicare & Medicaid Services (2012).  Chronic conditions among Medicare 
beneficiaries.  Retrieved March 31, 2013 from: http://www.cms.gov/Research-
Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-
Conditions/Downloads/2012Chartbook.pdf. 
 
Centers for Disease Control and Prevention (2012).  Falls among older adults: An 
overview.  Retrieved March 31, 2013 from: 
http://www.cdc.gov/homeandrecreationalsafety/falls/adultfalls.html. 
 
Centers for Disease Control and Prevention (2010).  Prevalence of doctor-diagnosed 
arthritis and arthritis attributable activity limitation: United States, 2007-2009.  
Morbidity and Mortality Weekly Report, 59(39), 1261-1265. 
 
Cherubini, A., Corsonello, A., Lattanzio, F. (2012).  Under prescription of beneficial 
medicines in older people: Causes, consequences, and prevention.  Drugs Aging, 
29(6), 463-475. 
 
Clyne, B., Bradley, M., Smith, S., Hughes, C., Motterlini, N., Clear, D., McDonnell, R., 
Williams, D., Fahey, T. (2013).  Effectiveness of medicines review with web-
based pharmaceutical treatment algorithms in reducing potentially inappropriate 
prescribing in older people in primary care: A cluster randomized trial (OPTI-
SCRIPT study protocol).  Trials, 14(72). 
 
 40 
Cockburn, J. (1997).  Prescribing behaviour in clinical practice: patients’ expectations 
and doctors’ perceptions of patients’ expectations-a questionnaire study.  British 
Medical Journal, 315, 520. 
 
Coggins, M. (2013).  Antihistamine Risks.  Aging Well, 6(2).  Retrieved on July 14, 2013 
from: http://www.todaysgeriatricmedicine.com/archive/0313p6.shtml. 
 
Dalleur O, Boland B, Spinewine A. (2012) 2012 Updated Beer’s criteria: Greater 
applicability to Europe? Journal of American Geriatrics Society, 60, 2188-2189. 
 
Dovjak, P. (2012).  Tools in polypharmacy: current evidence from observational and 
controlled studies.  Zeitschrift fur Gerontologie and Geriatrie, 6(45), 468-472.   
 
Ejaz, P., Bhojani, K., Joshi, V. (2004).  NSAIDs and kidney.  Journal of the Association 
of Physicians of India. 56, 632-640. 
 
Federal Interagency Forum on Aging Related Statistics (2010).  Older americans 2010: 
Key indicators of well-being.  Retrieved February 24, 2013, from: 
http://www.agingstats.gov/Main_Site/Data/2010_Documents/Population.aspx. 
 
Feinberg, J., Simonson, W. (2005).  Medication-related problems in the elderly: Defining 
the issues and identifying solutions.  Drugs Aging. 22, 559-569.   
 
Fick, D., Semla, T. (2012). 2012 American Geriatrics Society Beers criteria: New year, 
new criteria , new perspective.  Journal of American Geriatric Society, Retrieved 
Ampril 4, 2013, from: 
http://www.americangeriatrics.org/files/documents/beers/Perspective_JAGS.pdf.  
 
Fick, D., Cooper, J., Wade, W., Waller, J., Maclean, J., Beers, M. (2003).  Updating the 
Beers criteria for potentially inappropriate medication use in older adults: Results 
of a US consensus panel of experts.  Archives of Internal Medicine.163(22), 2716-
2724. 
 
Gallagher, P., Baeyens, J., Topinkova, E., Madlova, P., Cherubini, A., Gasperini, B., 
Cruz-Jentoft, A., Montero, B., Lang, P., Michel, J., O’Mahony, D. (2009).  Inter-
rater reliability of STOPP (Screening Tool of Older Persons’ Prescriptions) and 
START (Screening Tool to Alert doctors to Right Treatment) criteria amongst 
physicians in six European countries.  Age and Aging, 10, 603-606. 
 
Gallagher, P., O’Connor, M., O’Mahony, D. (2011).  Prevention of potentially 
inappropriate prescribing for elderly patients: A randomized control trial using 
STOPP/START criteria.  Clinical Pharmacology and Therapeutics, 89(6), 845-
854.     
 
 41 
Gallagher, P., O’Mahony, D. (2008).  STOPP (screening tool of older persons’ 
potentially  inappropriate prescriptions): Application to acutely ill elderly patients 
and  comparison with beer’s criteria.  Age and Ageing. 37, 673-679.   
 
Gallagher, P., Ryan, C., Byrne, S., Kennedy, J., O’Mahnoy, D. (2007). STOPP 
(Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to 
Alert doctors to Right Treatment. Consensus validation.  International Journal of 
Clinical Pharmacology and Therapeutics,  46(2),72-83. 
 
Gillespie, U., Alassaad, A., Hammarlund-Udenaes, M., Morlin, C., Henrohn, D., 
Bertilsson, M., Melhus, H. (2013). Effects of pharmacists’ interventions on 
appropriateness of prescribing and evaluation of the instruments’ (MAI, STOPP 
and STARTs’) ability to predict hospitalization--analyses from a randomized 
controlled trial.  Public Library of Science, 8(5). 
 
Hajjar, E., Cafiero, A., Hanlon, J. (2007) Polypharmacy in elderly patients.  The 
American Journal of Geriatric Pharmacotherapy, 5(4), 345-351. 
 
Hamilton, H., Gallagher, P., O’Mahony, D. (2009).  Inappropriate prescribing and 
adverse drug events in older people.  Biomedical Central Geriatrics 9(5).   
 
Hamilton, H., Gallagher, P., Ryan, C., Byrne, S., O’Mahony, D. (2010).  Potentially 
inappropriate medications defined by STOPP criteria and the risk of adverse drug 
events in older hospitalized patients.  Archives of Internal Medicine, 171(11), 
1013-1019. 
 
Hanlon, J., Schmader, K., Kornkowski, M. (1997). Adverse drug events in high risk older 
outpatients.  Journal of American Geriatric Society, 45, 945-948. 
 
Hegeman, J., van den Bemt, J., Duysens, J., Limbeek, J. (2009) NSAIDs and the risk of 
accidental falls in the elderly a systematic review.  Drug Safety. 32(6), 489-498. 
 
Hill-Tayler, B., Sketris, I., Hayden, J., Byrne, S., O’Sullivan, D., Christie, R. (2013).  
Application of the STOPP/START Criteria: A systematic review of the 
prevalence of potentially inappropriate prescribing in older adults, and evidence 
of clinical, humanistic and economic impact.  Journal of Clinical Pharmacology 
Therapy, DOI 10.1111/jcpt.12059. 
 
IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, 
NY: IBM Corp. 
 
International Osteoporosis Foundation (2013).  Facts and statistics.  Retrieved March 31, 
2013, from: http://www.iofbonehealth.org/facts-statistics#category-14.   
 
Jano, E., Aparasu, R. (2007).  Healthcare outcomes associated with Beer’s criteria: A 
systematic review.  The Annals of Pharmacotherapy, 41(3), 438-447. 
 42 
 
Kaufman, D., Kelly, J., Rosenberg, L.  Anderson, T., Mitchell, A. (2002) Recent patterns 
of medication use in the ambulatory adult population in the United States: The 
Slone survey.  Journal of American Medical Association, 287(3), 337-344.   
 
Kiebazk, G., Beinart, G., Perser, K., Ambrose, C., Siff, S., Heggeness, M. (2002).   
 Under-treatment of osteoporosis in men with hip fracture. Archive of Internal 
Medicine, 162, 2217-2222. 
 
Klotz, U. (2009).  Pharmacokinetics and drug metabolism in the elderly.  Drug 
Metabolism Reviews, 41(2), 67-76.  
 
Kojima, T., Akishita, M., Nakamura, T., Nomura, K., Ogawa, S., Iijima, K., Eto, M., 
Ouchi, Y. (2010) Polypharmacy as a risk for fall occurrence in geriatric 
outpatients.   Geriatrics & Gerontology International. 12, 425-430. 
 
Lang, P., Hasso, Y., Belmin, J., Payot, I., Baeyens, J., Vogt-Ferrier, N., Gallagher, P., 
O’Mahony, D., Michel, J. (2009).  STOPP-START: Adaptation en langue 
francaise d’un outil de detection de la prescription medicamenteuse inappropriee 
chez la personne agee.  Rev can sante pulique, 100(6), 426-431.   
 
 
Marcum, Z., Hanlon, J. (2012).  Commentary on the new American Geriatric Society 
Beer’s Criteria for potentially inappropriate medication use in older adults.  
American Journal of Geriatric Pharmacotherapy, 10(2), 151-159. 
 
NHS Cumbria Medicines Management Team (2013).  Clinical medication review: a 
practice guide.  Retrieved July 16, 2013 from: 
http://www.cumbria.nhs.uk/ProfessionalZone/MedicinesManagement/Guidelines/
MedicationReview-PracticeGuide2011.pdf. 
 
O’Mahony, D. (2012) Medication errors & STOPP/START criteria [PDF document].  
Retrieved from 
http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2012/04/
WC500125149.pdf. 
 
O’Mahony, D., Gallagher, P. (2008) Inappropriate prescribing in the older population: 
Need for new criteria.  Age and Aging 37, 138-141. 
 
O’Mahony, D., Gallagher, P., Ryan, C., Byrne, S., Hamilton, H., Barry, P., O’Connor, 
M., Kennedy, J. (2010).  STOPP & START criteria: A new approach to detecting 
potentially inappropriate prescribing in old age.  European Geriatric Medicine, 1, 
45-51. 
 
 43 
Onatade, R., Auyeung, V., Scutt, G., Fernando, J. (2013).  Potentially inappropriate 
prescribing in patients on admission and discharge from an older peoples’ unit of 
an acute UK hospital.  Drugs Aging, DOI 10.1007/s40266-013-0097-5. 
 
Opondo, D., Eslami, S., Visscher, S., Rooij, S., Verheij, R., Kroevaar, J., Abu-Hanna, A. 
(2012).  Inappropriateness of medication prescriptions to elderly patients in 
 primary care setting: A systematic review.  Public Library of Science. 
7(8), 1-10. 
 
Page, J. (2000).  Consumption of NSAIDs and the development of congestive heart 
failure in elderly patients: An underrecognized public health problem.  Archives of 
Internal Medicine, 160(6), 777-784. 
 
Parsons, C., Johnston, S., Mathie, E., Baron, N., Machen, I., Amador, S., Goodman, C. 
(2012).  Potentially inappropriate prescribing in older people with dementia in 
care homes: A retrospective analysis.  Drugs & Aging, 29(2), 143-155.   
 
Perry, M. (2011).  The problem of polypharmacy in the elderly.  Nurse Prescribing, 
9(7),347-349. 
 
Pham, C., Dickman, R. (2007).  Minimizing adverse drug events in older patients.  
American Family Physician, 76,1837-1844. 
 
Pretorius, R., Gataric, G., Swedlund, S., Miller, J. (2013).  Reducing the risk of adverse 
drug events in older adults.  American Family Physician, 87(5), 331-336. 
 
Ramaswamy, R., Maio, V., Diamon, J., Talati, A., Hartmann, C.,  Arenson, C., Roehl, B. 
(2010) Potentially inappropriate prescribing in elderly: Assessing doctor 
knowledge, confidence, and barriers.  Journal of Evaluation in Clinical Practice, 
17(6), 1153-1159. 
 
Resnick, B., Pacala J. (2012).  2012 Beers Criteria.  Journal of American Geriatric 
Society.  Retrieved on April 4, 2013 from: 
http://www.americangeriatrics.org/files/documents/beers/Editorial_JAGS.pdf. 
 
Roberts, A., Hopp, T., Sorensen, E., Benrimoj, S., Chen, T., Herborg, H., Williams, K., 
Aslani, P. (2003).  Understanding practice change in community pharmacy: A 
qualitative research instrument based on organisational theory.  Pharmacy World 
Science, 25(5); 227-234.   
 
Rochon, P., Gurwitz, J. (1997).  Optimising drug treatment for elderly people: the 
prescribing cascade.  British Medical Journal, 315, 1096-1099. 
 
Rosen, A., Karter, A., Liu, J., Selby, J., Schneider, E. (2004) Use of angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers in high-risk 
 44 
clinical and ethnic groups with diabetes. Journal of General Internal Medicine, 
19, 669-675. 
 
Ryan, C. (2011).  Screening tool of older persons’ prescriptions (STOPP) and screening 
tool to alert doctors to right treatment (START) criteria. [PDF document].  
Retrieved from  
http://www.farmaactueel.nl/webcasts/extern/ESCP2011n/PDF/Ryan.pdf.    
 
Ryan, C., O’Mahony, D., Kennedy, J., Weedle, P., Byrne, S. (2009) Potentially 
inappropriate prescribing in an Irish elderly population in primary care.  British 
Journal of Clinical Pharmacology, 68(6), 936-947.   
 
Shahezwan, M., Wahab, A., Nyfort-Hansen, K., Kowalski, S. (2012).  Inappropriate 
prescribing in hospitalised Australian elderly as determined by the STOPP 
criteria.  International Journal of Clinical Pharmacology, 34, 855-862.   
 
Sloane, P., Gruber-Baldini, A., Zimmerman, S., Roth, M., Watson, L., Boustant, M. 
(2004). Medication under-treatment in assisted living settings. Archives of 
Internal Medicine, 164, 2031-2037. 
 
Spinewine, A., Schmader, K., Barber, N., Hughes, C., Lapane, K., Swine, L., Hanlon, J., 
 (2007).  Appropriate prescribing in elderly people: How well can it be 
measured and optimized?  The Lancet, 370, 173-184.   
 
Steinman, M. (2007). Polypharmacy and the balance of medication benefits and risks.  
American Journal of Geriatric Pharmacotherapy, 5(4), 314-315.  
 
Taziaux, P. Franck, J., Ludovicy, R., Albert, A. (1996).  A study of general practitioners’ 
prescribing behaviour to the elderly in Wallonia, Belgium.  European Journal of 
Public Health, 6(1), 49-57. 
 
Therapeutic Research Center (2011).  STARTing and STOPPing medications in the 
elderly.  Prescriber’s Letter; Sept 2011, 1-14. 
 
Trivedi, D., Doll, R., Khaw, K., (2003) Effect of four monthly oral vitamin D3 
(cholecalciferol) supplementation on fractures and mortality in men and women 
living in the community: randomised double blind controlled trial. British 
Medical Journal, 326:469. 
 
Ubeda, A., Ferrandiz, L., Maicas, N., Gomez, C., Bonet, M., Peris, J. (2012). Potentially 
inappropriate prescribing in institutionalised older patients in Spain: The STOPP-
START criteria compared with the Beers criteria.  Pharmacy Practice, 10(2), 83-
91. 
 
U.S. General Accounting Office (1995).  Prescription drugs and the elderly.  AO/HEHS-
95-152.  Washington, DC: U.S. General Accounting Office.   
 45 
 
Vieira de Lima, T., Garbin C., Garbin, C., Garbin, A., Sumida, D., Saliba, O. (2013).  
Potentially inappropriate medications used by the elderly: Prevelence and risk 
factors in Brazilian care homes.  Biomedical Central Geriatrics, 13(52).   
 
Vishwas, H., Harugeri, A., Parthasarathi, G., Ramesh, M. (2011).  Potentially 
inappropriate medication use in indian elderly: Comparison of Beers’ criteria and 
Screening Tool of Older Persons’ potentially inappropriate Prescriptions.  
Geriatric Gerontology International, 12, 506-514. 
 
Werder, S., Preskorn, S. (2003).  Managing polypharmacy: Walking the fine line between 
help and harm.  Current Psychiatry, 2(2), 24-36.   
 
Whitaker, J. (2011). Preventing falls in older people: Assessment and interventions.  
Nursing Standard, 25(52), 50-55. 
 
Whitaker, M., Guo, J., Kehoe, T., Benson, G. (2012).  Bisphosphonates for osteoporosis: 
Where do we go from here?  New England Journal of Medicine 366, 2048-2051.   
 
Williams, C. (2002). Using medications appropriately in older adults.  American Family 
Physician, 66(10), 1917-1924.  
 
Windsant-van den Tweel, V., Verduijn, M., Derijks, H., van Marum, R. (2012).  
Detection of inappropriate medication use in the elderly: Will the STOPP and 
START criteria become the new Dutch standards? Ned Tijdschr Geneeskd, 
156(40). 
 
Yayla, M., Bilge, U., Binen, E., Keskin, A. (2013).  The use of START/STOPP Criteria 
for elderly patients in primary care.  The Scientific World Journal, DOI 
10.1155/2013/165873. 
 
Ziere, G., Dieleman, J., Hofman, A., Pols, H., Van der Cammen, T., Stricker, B. (2005).  
Polypharmacy and falls in the middle age and elderly population.  British Journal 
 of Clinical Pharmacology,  61(2), 218-223. 
 
 
 
 
 
 
 
 
 
 
 
 
 46 
Appendix A 
 
STOPP Criteria: (O’Mahony et al, 2010) 
Screening Tool of Older People’s potentially inappropriate Prescriptions 
 The following drug prescriptions are potentially inappropriate in persons aged 65 years 
of age. 
 
A. Central Nervous System & Psychotropic Drugs 
 1.Tricyclic antidepressants (TCAs) with dementia 
 2. TCAs with glaucoma 
 3. TCAs with cardiac conductive abnormalities 
 4. TCAs with constipation 
 5. TCAs with an opiate or calcium channel blocker 
 6. TCAs with prostatism or prior history of urinary retention 
 7. Long-term (>1month) long acting benzodiazepines  
 8. Long-term (>1month) neuroleptics as long-term hypnotics 
 9. Long-term (>1month) neuroleptics in those with Parkinsons 
 10. Phenothiazines in patients with epilepsy 
 11. Anticholinergics to treat extrapyramidal side effects of neuroleptic 
medications 
 12. Selective serotonin re-uptake inhibitors (SSRIs) with a history of clinically  
 significant hyponatraemia 
 13. Prolonged use (>1week) of first generation antihistamines 
 
B. Musculoskeletal System Drugs 
 1. Non-steroidal anti-inflammatory drug (NSAID) with history of peptic ulcer  
 disease or gastrointestinal bleeding, unless with concurrent histamine H2  
 receptor antagonist, PPI, or misoprostol  
 2. NSAID with moderate-severe hypertension (moderate: 160/100-179/100;  
 severe 180/110) 
 3. NSAID with heart failure 
 4. Long-term use of NSAID (>3months) for symptoms relief of mild osteoarthritis 
 5. Warfarin and NSAID together 
 6. NSAID with chronic renal failure (Serum Cr >150, GFR 20-50 ml/min) 
 7. Long term corticosteroid use (>3months) as monothearpy for rheumatoid  
 arthritis or osteoarthritis  
 8. Long term NSAID or colchicine for chronic treatment of gout where there is no 
  contraindication to allopurinol. 
C. Drugs that Adversely Affect Fallers 
 1. Benzodiazepines 
 2. Neuroleptic drugs 
 3. First-generation antihistamines 
 4. Vasodilator drugs with persistent postural hypotension (recurrent >20mmHg  
 drop in systolic BP) 
 5. Long-term opiates in those with recurrent falls 
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D. Analgesic Drugs 
 1. Use of long-term powerful opiates as first line therapy for mild to moderate  
 pain. 
 2. Regular opiates for >2weeks in those with chronic constipation without  
 concurrent use of laxatives 
 3. Long-term opiates in those with dementia unless indicated for palliative care or 
 management of moderate-severe chronic pain syndrome 
 
START Criteria: 
 Screening Tool to Alert doctors to Right i.e. appropriate, indicated Treatment. 
These medications should be considered for people 65 years of age with the following 
conditions, where no contraindication to prescription exists. 
 
A. Musculoskeletal System Drugs 
 1. Disease-modifying antirheumatic drug with active moderate-severe rheumatoid 
  disease lasting >12 weeks. 
 2. Bisphosphonates in patients taking maintenance corticosteroid therapy 
 3. Calcium supplement in patients with known osteoporosis (previous fragility  
 fracture, acquired dorsal kyphosis) 
           4.Vitamin D in patients with known osteoporosis (previous fragility fracture,  
 acquired dorsal kyphosis) 
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Appendix B 
 
Beer’s Criteria (American Geriatric Society, 2012) 
Organ System/Therapeutic Category/Drug(s)-Independent of Diagnosis 
 First Generation antihistamines (as a single agent or part of combination products) 
  -Brompheniramine 
  -Carbinoxamine 
  -Chlorpheniramine 
  -Clemastine 
  -Cyproheptadine 
  -Dexbrompheniramine 
  -Dexchlorpheniramine 
  -Diphenhydramine (oral) 
  -Doxylamine 
  -Hydroxyzine 
  -Promethazine 
  -Triprolidine  
 Pain Medications 
  Meperidine 
  Non-COX-selective NSAIDs, oral 
   -Aspirin >325mg/day 
   -Diclofenac (oral) 
   -Diflunisal 
   -Etodolac 
   -Fenoprofen 
   -Ibuprofen 
   -Ketoprofen 
   -Meclofenamate 
   -Mefenamic acid 
   -Meloxicam 
   -Nabumetone 
   -Naproxen 
   -Oxaprozin 
   -Piroxicam 
   -Sulindac 
   -Tolmetin 
  Indomethacin 
  Ketorolac (includes parenteral) 
  Pentazocine 
  Skeletal Muscle Relaxants 
   -Carisoprodol 
   -Chlorzoxazone 
   -Cyclobenzaprine 
   -Metaxalone 
   -Methocarbamol 
   -Orphenadrine 
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Disease or Syndrome; Drugs-Considering Diagnosis 
 History of falls or fractures 
  Anticonvulsants 
  Antipsychotics 
  Benzodiazepines 
  Non-Benzodiazepine hypnotics 
   -Eszopiclone 
   -Zaleplon 
   -Zolpidem 
  TCAs/SSRIs 
 History of gastric or duodenal ulcers 
  -Aspirin (>325mg/) 
  -Non-COX-2 selective NSAIDs 
 Chronic kidney disease sages IV and V 
  -NAIDs 
  -Triamterene (alone or in combination)  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix C 
Demographic Data Collection Tool 
Patient Identifier #: 1-63  
Age:  
Gender:  
Race/Ethnicity:  
Allergies:  
Insurance provider:  
Past Medical History (exclude terminally ill; include those with OP, OA, rheumatoid arthritis 
(RA), gout, atrial fibrillation, hypertension, congestive heart failure, peptic ulcer disease, 
gastrointestinal bleed, renal failure, chronic pain, Parkinson’s, anxiety, depression, insomnia, or 
seasonal allergies):  
Heart rate:  
BP: (no hypertension, moderate hypertension-160-179/100, severe hypertension-180/110)  
Hospitalizations in last year:  
History of falls in last 3 months:  
Current Medications (including prescription and OTC/supplements): 
